CCRL2 affects the sensitivity of myelodysplastic syndrome and secondary acute myeloid leukemia cells to azacitidine

Better understanding of the biology of resistance to DNA methyltransferase (DNMT) inhibitors is required to identify therapies that can improve their efficacy for patients with high-risk myelodysplastic syndrome (MDS). CCRL2 is an atypical chemokine receptor that is upregulated in CD34+ cells from MDS patients and induces proliferation of MDS and secondary acute myeloid leukemia (sAML) cells. In this study, we evaluated any role that CCRL2 may have in the regulation of pathways associated with poor response or resistance to DNMT inhibitors. We found that CCRL2 knockdown in TF-1 cells downregulated DNA methylation and PRC2 activity pathways and increased DNMT suppression by azacitidine in MDS/sAML cell lines (MDS92, MDS-L and TF-1). Consistently, CCRL2 deletion increased the sensitivity of these cells to azacitidine in vitro and the efficacy of azacitidine in an MDS-L xenograft model. Furthermore, CCRL2 overexpression in MDS-L and TF-1 cells decreased their sensitivity to azacitidine. Finally, CCRL2 levels were higher in CD34+ cells from MDS and MDS/myeloproliferative neoplasm patients with poor response to DNMT inhibitors. In conclusion, we demonstrated that CCRL2 modulates epigenetic regulatory pathways, particularly DNMT levels, and affects the sensitivity of MDS/sAML cells to azacitidine. These results support CCRL2 targeting as having therapeutic potential in MDS/sAML.

[1]  M. Andreeff,et al.  Azacitidine plus venetoclax in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: phase 1 results of a single-centre, dose-escalation, dose-expansion, phase 1-2 study. , 2022, The Lancet. Haematology.

[2]  R. Varadhan,et al.  Genomic landscape of myelodysplastic/myeloproliferative neoplasm can predict response to hypomethylating agent therapy , 2022, Leukemia & lymphoma.

[3]  R. Varadhan,et al.  The role of the atypical chemokine receptor CCRL2 in myelodysplastic syndrome and secondary acute myeloid leukemia , 2021, bioRxiv.

[4]  T. Karantanos,et al.  Biology and clinical management of hypoplastic MDS: MDS as a bone marrow failure syndrome. , 2021, Best practice & research. Clinical haematology.

[5]  R. Varadhan,et al.  Gender‐related differences in the outcomes and genomic landscape of patients with myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes , 2021, British journal of haematology.

[6]  D. Faller,et al.  Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML , 2021, Leukemia.

[7]  S. Sozzani,et al.  Molecular Basis for CCRL2 Regulation of Leukocyte Migration , 2020, Frontiers in Cell and Developmental Biology.

[8]  E. Leifer,et al.  A Multi-Center Biologic Assignment Trial Comparing Reduced Intensity Allogeneic Hematopoietic Cell Transplantation to Hypomethylating Therapy or Best Supportive Care in Patients Aged 50-75 with Advanced Myelodysplastic Syndrome: Blood and Marrow Transplant Clinical Trials Network Study 1102 , 2020, Transplantation and Cellular Therapy.

[9]  S. Karanika,et al.  Sex determines the presentation and outcomes in MPN and is related to sex-specific differences in the mutational burden. , 2020, Blood advances.

[10]  Liping Liu,et al.  Mycobacterium tuberculosis Heat-Shock Protein 16.3 Induces Macrophage M2 Polarization Through CCRL2/CX3CR1 , 2019, Inflammation.

[11]  Xiaomei Ma,et al.  Epidemiology of myelodysplastic syndromes: Why characterizing the beast is a prerequisite to taming it. , 2019, Blood reviews.

[12]  O. Fuchs Recent Developments in Myelodysplastic Syndromes , 2019 .

[13]  Duonan Yu,et al.  Gender disparity in the survival of patients with primary myelodysplastic syndrome , 2019, Journal of Cancer.

[14]  P. Skipp,et al.  Proteomic Analysis of Azacitidine-Induced Degradation Profiles Identifies Multiple Chromatin and Epigenetic Regulators Including Uhrf1 and Dnmt1 as Sensitive to Azacitidine. , 2019, Journal of proteome research.

[15]  A. Letai,et al.  Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. , 2019, Blood.

[16]  T. Shi,et al.  Multiomics of azacitidine-treated AML cells reveals variable and convergent targets that remodel the cell-surface proteome , 2018, Proceedings of the National Academy of Sciences.

[17]  Frederik Otzen Bagger,et al.  BloodSpot: a database of healthy and malignant haematopoiesis updated with purified and single cell mRNA sequencing profiles , 2018, Nucleic Acids Res..

[18]  Y. Tohyama,et al.  An MDS-derived cell line and a series of its sublines serve as an in vitro model for the leukemic evolution of MDS , 2018, Leukemia.

[19]  Xiaomei Ma,et al.  Long-term survival of older patients with MDS treated with HMA therapy without subsequent stem cell transplantation. , 2018, Blood.

[20]  A. Mantovani,et al.  The atypical receptor CCRL2 is required for CXCR2-dependent neutrophil recruitment and tissue damage. , 2017, Blood.

[21]  Susan R. Wilson,et al.  Integrative Genomics Identifies the Molecular Basis of Resistance to Azacitidine Therapy in Myelodysplastic Syndromes. , 2017, Cell reports.

[22]  D. Maucort-Boulch,et al.  An miRNA–DNMT1 Axis Is Involved in Azacitidine Resistance and Predicts Survival in Higher-Risk Myelodysplastic Syndrome and Low Blast Count Acute Myeloid Leukemia , 2016, Clinical Cancer Research.

[23]  R. Dummer,et al.  Senescent fibroblast-derived Chemerin promotes squamous cell carcinoma migration , 2016, Oncotarget.

[24]  B. Broom,et al.  Caveolin-1 regulates hormone resistance through lipid synthesis, creating novel therapeutic opportunities for castration-resistant prostate cancer , 2016, Oncotarget.

[25]  Sheng Wei,et al.  IL8-CXCR2 pathway inhibition as a therapeutic strategy against MDS and AML stem cells. , 2015, Blood.

[26]  H. Kantarjian,et al.  Outcome of patients with low‐risk and intermediate‐1‐risk myelodysplastic syndrome after hypomethylating agent failure: A report on behalf of the MDS Clinical Research Consortium , 2015, Cancer.

[27]  G. Garcia-Manero,et al.  An MDS xenograft model utilizing a patient-derived cell line , 2014, Leukemia.

[28]  M. Voso,et al.  Expression of nucleoside-metabolizing enzymes in myelodysplastic syndromes and modulation of response to azacitidine , 2013, Leukemia.

[29]  H. Hsu,et al.  MDM2 Overexpression Deregulates the Transcriptional Control of RB/E2F Leading to DNA Methyltransferase 3A Overexpression in Lung Cancer , 2012, Clinical Cancer Research.

[30]  Jie Shen,et al.  Expression of DNMT1 and DNMT3a Are Regulated by GLI1 in Human Pancreatic Cancer , 2011, PloS one.

[31]  B. Esterni,et al.  Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  N. Van Rooijen,et al.  5-Azacytidine enhances the anti-leukemic activity of lintuzumab (SGN-33) in preclinical models of acute myeloid leukemia , 2010, mAbs.

[33]  R. Ganetzky,et al.  Phase I combination trial of lenalidomide and azacitidine in patients with higher-risk myelodysplastic syndromes. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  C. Hsiao,et al.  Crystal structure of the human FOXO3a-DBD/DNA complex suggests the effects of post-translational modification. , 2008, Nucleic acids research.

[35]  John D. Storey,et al.  Capturing Heterogeneity in Gene Expression Studies by Surrogate Variable Analysis , 2007, PLoS genetics.

[36]  M. Newton,et al.  Fundamental differences in cell cycle deregulation in human papillomavirus-positive and human papillomavirus-negative head/neck and cervical cancers. , 2007, Cancer research.

[37]  H. Heslop,et al.  T lymphocytes redirected against the kappa light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells. , 2006, Blood.

[38]  B. Cheson,et al.  Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. , 2006, Blood.

[39]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[40]  M. Day,et al.  Regulation of DNA methyltransferase 1 by the pRb/E2F1 pathway. , 2005, Cancer research.

[41]  J. Christman,et al.  5-Azacytidine and 5-aza-2′-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy , 2002, Oncogene.

[42]  N. C. Price,et al.  Mechanism-based inhibition of C5-cytosine DNA methyltransferases by 2-H pyrimidinone. , 1999, Journal of molecular biology.

[43]  J. Mesirov,et al.  The Molecular Signatures Database (MSigDB) hallmark gene set collection. , 2015, Cell systems.

[44]  C. Plass,et al.  The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells , 2009, Leukemia.